



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450

FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
William J. Roberts	1400-004	8577
	EXAMINER	
	QAZI, SABIHA NAIM	
	ART UNIT	PAPER NUMBER
	1616 DATE MAILED: 06/04/2003	17
	1	William J. Roberts 1400-004 EXAM QAZI, SAB ART UNIT 1616

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
		10/053,505	ROBERTS, WILLIAM J.	
	Office Action Summary	Examiner	Art Unit	
	•	Sabiha Naim Qazi	1616	
	The MAILING DATE of this communication app	ars on the cover sh et with the c	orrespondence address	
Period for Reply				
THE - Exte after - If the - If NC - Failu - Any I	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. a period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we use to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).	
Status 1)□	Responsive to communication(s) filed on 16 J	anuany 2002		
2a)□	<u> </u>	s action is non-final.		
3)	, _		nsecution as to the merits is	
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
	ion of Claims			
4) Claim(s) <u>1-58</u> is/are pending in the application.				
-: - -	4a) Of the above claim(s) <u>11-58</u> is/are withdrawn from consideration.			
	Claim(s) is/are allowed.	garage and the second s	•	
	6) Claim(s) <u>1-10</u> is/are rejected.			
	7) Claim(s) is/are objected to.			
8) Claim(s) <u>11-58</u> are subject to restriction and/or election requirement. Application Papers				
9) The specification is objected to by the Examiner.				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.				
12) The oath or declaration is objected to by the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120				
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:				
	1. Certified copies of the priority documents have been received.			
	2. Certified copies of the priority documents have been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).				
a) ☐ The translation of the foreign language provisional application has been received.				
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.				
Attachmen				
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>21</u>	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)	



Application/Control Number: 10/053,505

Art·Unit: 1616

plication/Control Number: 10/055,500

Acknowledgement is made of the response filed in paper no. 10 dated 3/18/03.

Amendments are entered. Claims 1-10 and 59-74 are pending. No claim is allowed.

Arguments are found persuasive therefore rejections are withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 59-73 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

New claims are drawn to specific alkyl chain carbonate ester which was not disclosed in the specification.. Applicant must limit the invention according to the support in the disclosure.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.



Application/Control Number: 10/053,505

Art Unit: 1616

£

Claim 1 as written is confusing. It is unclear what is intended by this claim. It appears that Applicant's are claiming androstene-4-ene-3 alpha, 17 beta-diol, 17 beta alkylcarbonates. The language should be clear.

Furthermore, it is also not clear what "comprises" means in a compound claim. When complete compound is defined than what is the meaning of "comprising" in these claims. What else can be added to the structures of these compounds? A clarification is required. Note, that the claims are not drawn to the compositions. The claimed compounds can be represented by a generic formula.

The term including in claim 7 is open ended. This term should be deleted.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-10 are rejected under 35 U.S.C. 102(b) as being anticipated by A-100 (4-androstene-diolethyl carbonate ester) by MTE Nutrition. This dietary supplement is available through internet. (A copy of the document is enclosed).

Claims 1-10 are rejected under 35 U.S.C. 102(b) as being anticipated by Chem Net , Taizhou Xingye Chemical Co. Ltd., the product sold is 4-androstenediol Methyl Carbonate and 4-androstenediol Ethyl Carbonate (copy enclosed). These compounds are claimed by Applicant.

Page 4

Application/Control Number: 10/053,505

Art Unit: 1616

Claims 1-10 are rejected under 35 U.S.C. 102(b) as being anticipated by Twin

Lab Products, the product sold is "Andro Nitrate Fuel", 4-androstenediol Diethyl

Carbonate ester (copy enclosed). These compounds are claimed by Applicant.

Claims 1-10 are rejected under 35 U.S.C. 102(b) as being anticipated by A-100

(4-androstene-diol ethyl carbonate ester) by Biotest Mag 10. This compound is claimed

in present invention.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Sabiha Naim Qazi whose telephone number is 703-305-

3910. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Jose Dees can be reached on 703-308-4628. The fax phone numbers for

the organization where this application or proceeding is assigned are 703-308-4556 for

regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is 703-308-

1235.

June 2, 2003

SABIHA QAZI, PH.D PRIMARY EXAMINER